Regencell Bioscience (NASDAQ:RGC) Hits New 1-Year Low – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares hit a new 52-week low on Wednesday . The stock traded as low as $5.80 and last traded at $6.09, with a volume of 445073 shares. The stock had previously closed at $6.19.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience presently has an average rating of “Sell”.

Regencell Bioscience Trading Down 20.7%

The company has a 50 day moving average price of $21.36 and a 200 day moving average price of $25.32.

Regencell Bioscience (NASDAQ:RGC) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE boosted its holdings in Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares in the last quarter. Amundi acquired a new stake in shares of Regencell Bioscience in the 1st quarter valued at approximately $219,000. Seven Fleet Capital Management LP acquired a new stake in shares of Regencell Bioscience in the 4th quarter valued at approximately $92,000. Vident Advisory LLC grew its holdings in Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after acquiring an additional 11,866 shares during the period. Finally, Hudson Bay Capital Management LP purchased a new position in Regencell Bioscience in the fourth quarter worth $275,000. 0.13% of the stock is currently owned by institutional investors and hedge funds.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.